Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Investigative Radiology

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.rli.0000112789.57341.01PMID 15076005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ProHance story: the making of a novel MRI contrast agent

  1997cited by this paper
• Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents.

  1996cited by this paper
• Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats

  1995cited by this paper
• Magnetic resonance contrast agents for neuroimaging. Safety issues.

  1994cited by this paper
• Stability assessment of gadolinium complexes by P‐31 and H‐1 relaxometry

  1994cited by this paper
• Stability of Gadolinium Complexes In Vitro and In Vivo

  1993cited by this paper
• Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.

  1993cited by this paper
• Quantification of dechelation of gadopentetate dimeglumine in rats.

  1992cited by this paper
• Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.

  1992cited by this paper
• Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.

  1992cited by this paper
• Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA.

  1992cited by this paper
• Metal ion release from paramagnetic chelates: What is tolerable?

  1991cited by this paper
• Changes of quantal transmitter release caused by gadolinium ions at the frog neuromuscular junction

  1991cited by this paper
• Reaction of gadolinium chelates with endogenously available ions.

  1991cited by this paper
• Gadolinium blocks low- and high-threshold calcium currents in pituitary cells.

  1990cited by this paper
• The relationship between thermodynamics and the toxicity of gadolinium complexes.

  1990cited by this paper
• Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67.

  1990cited by this paper
• Cerebral Erdheim-Chester disease: persistent enhancement with Gd-DTPA on MR images.

  1989cited by this paper
• Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.

  1984cited by this paper

• Coordination clusters as emerging magnetic resonance imaging contrast agents

  2025cites this paper
• Fetal Safety in MRI During Pregnancy: A Comprehensive Review

  2025cites this paper
• Gadolinium Deposition in Bone Tissues After Contrast-enhanced Magnetic Resonance Imaging

  2025cites this paper
• Gadolinium and Its Effects on Nutritional Status, Microscopy and Microanalytical Outcomes: Quantification by ICP‐MS and Incidence on Reproductive Tract and Liver of Wistar Rats

  2025cites this paper
• Symptoms Associated With Gadolinium Exposure

  2025cites this paper
• Gadolinium Elimination in a Gadolinium Deposition Disease Population After a Single Exposure to Gadolinium-Based Contrast Agents

  2024cites this paper
• Vueway™ (Gadopiclenol): Practical Considerations for Use

  2024cites this paper
• The glymphatic system and multiple sclerosis: An evolving connection.

  2024cites this paper
• Generative Adversarial Network Based Contrast Enhancement: Synthetic Contrast Brain Magnetic Resonance Imaging.

  2024cites this paper
• Magnetic resonance imaging short protocols for intraductal papillary mucinous neoplasm (IPMN) surveillance: The time has come.

  2024cites this paper
• Elemental Bioimaging of Sheep Bone and Articular Cartilage After Single Application of Gadolinium-Based Contrast Agents

  2023cites this paper
• Update on Gadolinium Based Contrast Agent Safety, From the AJR Special Series on Contrast Media.

  2023cites this paper
• Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium

  2023cites this paper
• Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination

  2023cites this paper
• Gadolinium Deposition Disease: Current State of Knowledge and Expert Opinion.

  2023cites this paper
• Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy

  2023cites this paper
• A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body

  2023cites this paper
• Gadolinium-Based Contrast Agents and Free Gadolinium Inhibit Differentiation and Activity of Bone Cell Lineages

  2023cites this paper
• Combined speciation analysis and elemental bioimaging provides new insight into gadolinium retention in kidney.

  2022cites this paper
• Gadolinium Retention after Contrast-Enhanced Magnetic Resonance Imaging: A Narratative Review

  2022cites this paper
• Dynamic Nuclear Polarization for Sensitivity Enhancement in Biomolecular Solid-State NMR.

  2022cites this paper
• Toxicity of rare earth elements: An overview on human health impact

  2022cites this paper
• The Impact of Dense Breasts on the Stage of Breast Cancer at Diagnosis: A Review and Options for Supplemental Screening

  2022cites this paper
• Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide.

  2022cites this paper
• Elemental Imaging of Long-term Gadolinium Retention in Rodent Femur.

  2022cites this paper
• Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience.

  2022cites this paper
• Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

  2022cites this paper
• Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure

  2022cites this paper
• Su Numunelerinde Spektrofotometrik Gadolinyum Tayini

  2022cites this paper
• Dynamic Serial Cytokine Measurements During Intravenous Ca-DTPA Chelation in Gadolinium Deposition Disease and Gadolinium Storage Condition

  2021cites this paper
• Gadolinium Deposition and Liver MRI

  2021cites this paper
• Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting

  2021cites this paper
• Safety issues related to intravenous contrast agent use in magnetic resonance imaging

  2021cites this paper
• MRI in Pregnancy and Precision Medicine: A Review from Literature

  2021cites this paper
• Physicians with self-diagnosed gadolinium deposition disease: a case series

  2021cites this paper
• How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo

  2021cites this paper
• Signal Intensity Changes in the Dentate Nucleus and Globus Pallidus of Multiple Sclerosis Patients Undergoing Multiple Brain Magnetic Resonance Imaging with Gadolinium-Based Contrast Agents

  2021cites this paper
• Mild Dissolution/Recomplexation Strategy for Speciation Analysis of Gadolinium from MR Contrast Agents in Bone Tissues by Means of HPLC-ICP-MS.

  2021cites this paper
• Effect of formalin fixation on measured concentrations of deposited gadolinium in human tissue: an autopsy study

  2021cites this paper
• Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2

  2021cites this paper
• Gadolinium Retention in Brain and Body: Clinical and Preclinical Evidence

  2021cites this paper
• Chemistry, Physicochemical Properties and Pharmacokinetics of Gadolinium-Based Contrast Agents

  2021cites this paper
• What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems?

  2021cites this paper
• Toxicity associated with gadolinium-based contrast-enhanced examinations

  2021cites this paper
• Stability of MRI contrast agents in high-energy radiation of a 1.5 T MR-linac.

  2021cites this paper
• Screening Breast MRI and Gadolinium Deposition: Cause for Concern?

  2021cites this paper
• Magnetic Resonance Enterography in the Diagnosis of Crohn’s Disease Using Diffusion-Weighted Imaging with Background Body Signal Suppression (DWIBS) Sequence

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Pneumococcal vaccine

  2020cites this paper
• Gadolinium-Based Contrast Agents for Breast MRI and Uncertainties About Brain Gadolinium Retention

  2020cites this paper
• Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Gadolinium Retention in the Central and Peripheral Nervous System: Implications for Pain, Cognition, and Neurogenesis.

  2020cites this paper
• Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks

  2020cites this paper
• Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats

  2020cites this paper
• Magnetic Resonance Safety: Pregnancy and Lactation.

  2020cites this paper
• Establishing Reference Intervals for Gadolinium Concentrations in Blood, Plasma, and Urine in Individuals Not Previously Exposed to Gadolinium-Based Contrast Agents

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia.

  2020cites this paper
• Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles

  2020cites this paper
• Detection and imaging of gadolinium accumulation in human bone tissue by micro- and submicro-XRF

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Ilze Apine ORCID 0000-0001-9425-7568 Magnetic resonance enterography in the diagnosis of Crohn’s disease using diffusion-weighted imaging with background body signal suppression (DWIBS) sequence Summary of the Doctoral Thesis for obtaining the doctoral degree (PhD)

  2020cites this paper
• Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention Gadolinium-haltige Kontrastmittel nach anaphylaktoiden Reaktionen, nephrogener systemischer Fibrose und Hirnretention – was haben wir gelernt?

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• Radiological contrast agents and radiopharmaceuticals

  2020cites this paper
• Role of gadolinium-based contrast agents in neurological disorders.

  2020cites this paper
• Risks and Benefits of Gadolinium-Based Contrast Enhanced MRI.

  2020cites this paper
• Comparison of Gadolinium Contrast Agent Retention in Patients Receiving Multiple Contrast-enhanced MRI Exams

  2020cites this paper
• Manganese Complex of a Rigidified 15-Membered Macrocycle: A Comprehensive Study.

  2020cites this paper
• Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats

  2020cites this paper
• Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations

  2020cites this paper
• Contrast media in patients with kidney disease: An update

  2020cites this paper
• The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?

  2019cites this paper
• Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.

  2019cites this paper
• Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents

  2019cites this paper
• Gadolinium-based contrast agents: from gadolinium complexes to colloidal systems.

  2019cites this paper
• Gadoliniumablagerungen – Morbus Gadolinium

  2019cites this paper
• Gadolinium-based contrast agents — review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients

  2019cites this paper
• Pre-hepatic and pre-pancreatic transplant donor evaluation.

  2019cites this paper
• In vivo detection of retained gadolinium in bone by x-ray fluorescence following administration of gadolinium-based contrast agents used in MRI

  2019cites this paper
• Yttrium-86 is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents.

  2019cites this paper
• The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

  2019cites this paper
• Erhöhte Signalintensitäten und Gadolinium-Werte im Gehirn nach Gabe Gadolinium-haltiger MR-Kontrastmittel

  2019cites this paper
• Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy?

  2019cites this paper
• The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain.

  2019cites this paper
• Decreased native renal T1 up to one week after gadobutrol administration in healthy volunteers

  2019cites this paper
• Stability evaluation of Gd chelates for macromolecular MRI contrast agents

  2019cites this paper
• Gadolinium Deposition and Retention in the Brain: Should We Be Concerned?

  2019cites this paper
• Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure.

  2018cites this paper
• Self-identified gadolinium toxicity: comparison of gadolinium in bone and urine to healthy gadolinium-based contrast agent exposed volunteers

  2018cites this paper
• T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter

  2018cites this paper
• Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement

  2018cites this paper
• Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?

  2018cites this paper
• Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

  2018cites this paper
• The Critical Need for Pediatric and Juvenile Animal Research Addressing Gadolinium Retention in the Developing Body.

  2018cites this paper
• Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives

  2018cites this paper
• Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

  2018cites this paper